<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Premature ventricular complexes: Treatment and prognosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Premature ventricular complexes: Treatment and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Premature ventricular complexes: Treatment and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Antonis S Manolis, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hugh Calkins, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 07, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1730882170"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Premature ventricular complexes/contractions (PVCs; also referred to premature ventricular beats, premature ventricular depolarizations, or ventricular extrasystoles) are common and occur in a broad spectrum of the population. This includes patients without apparent structural heart disease as well as those with any form of cardiac disease, independent of severity.</p><p>The approach to risk assessment and treatment of PVCs along with information on prognosis will be presented here. Discussion of the prevalence, mechanisms, clinical presentation, and approach to diagnostic testing for patients with known or suspected PVCs, as well as review of supraventricular premature beats, are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/994.html" rel="external">"Premature ventricular complexes: Clinical presentation and diagnostic evaluation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/932.html" rel="external">"Supraventricular premature beats"</a>.)</p><p></p><p class="headingAnchor" id="H154964839"><span class="h1">RISK ASSESSMENT</span><span class="headingEndMark"> — </span>The management of the patient with PVCs depends on whether the initial evaluation indicates that the patient is at high versus low risk of complications including cardiomyopathy, heart failure exacerbation, and ventricular tachyarrhythmias. High-risk features will indicate more intensive treatment and monitoring. </p><p>Our approach, outlined below, is in general agreement with the published recommendations of multiple professional societies [<a href="#rid1">1-3</a>].</p><p class="headingAnchor" id="H3679285676"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>Most patients with PVCs have no symptoms; only a minority describe bothersome symptoms (usually palpitations). These PVC-related symptoms are described separately. (See  <a class="medical medical_review" href="/z/d/html/994.html" rel="external">"Premature ventricular complexes: Clinical presentation and diagnostic evaluation", section on 'Symptoms'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with no or mild PVC symptoms and none of the other risk factors described below can typically be reassured by their providers that PVCs are usually self-limiting, rarely life-threatening, and in most cases do not require treatment. (See <a class="local">'Asymptomatic patients with low premature ventricular complex burden'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with significant and/or persistent PVC-related symptoms should be treated to reduce the PVC burden; the treatment approach will depend upon the presence or absence of other risk factors. (See <a class="local">'Patient with symptoms and/or high premature ventricular complex burden'</a> below and <a class="local">'Premature ventricular complex burden'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms of syncope (especially with no prodrome or preceded by palpitations), chest pain, or dyspnea are uncommonly reported in patients with PVCs and signal underlying cardiac structural or electrical conduction system disease. These symptoms may identify a higher-risk patient and require specific evaluation. (See <a class="local">'Underlying or associated cardiac disease'</a> below.) </p><p></p><p class="headingAnchor" id="H2315824597"><span class="h2">Family history</span><span class="headingEndMark"> — </span>A detailed family history should be taken regarding coronary heart disease, sudden death, or arrythmia and cardiomyopathy. </p><p>A family history of sudden cardiac death or arrest or an inherited arrythmia syndrome identifies the patient to be at higher risk for electrical or structural heart disease, which in turn requires a more specific evaluation. (See <a class="local">'Further testing in selected patients'</a> below.)</p><p class="headingAnchor" id="H2719238726"><span class="h2">Premature ventricular complex burden</span><span class="headingEndMark"> — </span>In all patients, it is important to assess and then continue to monitor for reduction in PVC burden throughout treatment. High PVC burden is a predictor of PVC-induced cardiomyopathy, heart failure, and mortality, and therefore requires more aggressive therapy [<a href="#rid4">4</a>].</p><p>Monitoring can usually be done with 24- to 48-hour continuous electrocardiographic monitoring. (See  <a class="medical medical_review" href="/z/d/html/958.html" rel="external">"Ambulatory ECG monitoring", section on 'Continuous ambulatory ECG (Holter) monitor'</a>.) </p><p>PVC burden is classified as:</p><p class="bulletIndent1"><span class="glyph">●</span>Low: &lt;1 percent or 1000 PVCs/day </p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate burden: &gt;1 to &lt;15 percent PVCs/ day</p><p class="bulletIndent1"><span class="glyph">●</span>High: &gt;15 percent or 15,000 PVCs/day </p><p></p><p class="headingAnchor" id="H206759885"><span class="h2">Premature ventricular complex characteristics</span><span class="headingEndMark"> — </span>PVC characteristics such as origin and morphology can be considered when determining whether a patient is at high or low risk for cardiomyopathy or malignant arrythmia. Even when the PVCs seem to be idiopathic in a patient with a previously normal heart, some PVCs can still be potentially malignant (ie, cause cardiomyopathy, or trigger sudden death) [<a href="#rid5">5-7</a>]. PVC morphology is also of value as it can predict the ablation target and response to PVC catheter ablation. (See <a class="local">'Catheter ablation'</a> below.)</p><p>Characteristics associated with higher risk include increased QRS duration [<a href="#rid8">8,9</a>] (these are often of epicardial origin [<a href="#rid10">10-12</a>])  (<a class="graphic graphic_waveform graphicRef139336" href="/z/d/graphic/139336.html" rel="external">waveform 1</a>), interpolated PVCs [<a href="#rid13">13</a>]  (<a class="graphic graphic_waveform graphicRef72768" href="/z/d/graphic/72768.html" rel="external">waveform 2</a>), PVCs involving the Purkinje system (these can trigger ventricular fibrillation and have a short coupling interval figure [<a href="#rid14">14-16</a>]), and polymorphic PVCs [<a href="#rid17">17</a>]  (<a class="graphic graphic_waveform graphicRef139350" href="/z/d/graphic/139350.html" rel="external">waveform 3</a>). PVCs with highly variable coupling interval (&gt;60 ms) have been identified as originating in unusual areas (aortic sinuses of Valsalva, great cardiac vein) and have been associated with a higher risk for cardiac events [<a href="#rid18">18</a>]. In the same context, greater PVC coupling interval heterogeneity has been associated with both reduced LV function and an increased risk of developing heart failure [<a href="#rid19">19</a>]. Right and left ventricular outflow tract PVCs morphologies have also been associated with malignant ventricular arrhythmias [<a href="#rid5">5,20,21</a>]  (<a class="graphic graphic_waveform graphicRef139343" href="/z/d/graphic/139343.html" rel="external">waveform 4</a> and <a class="graphic graphic_waveform graphicRef139349" href="/z/d/graphic/139349.html" rel="external">waveform 5</a>).</p><p>In patients without apparent heart disease, frequent, complex, and polymorphic PVCs have been associated with worse prognosis [<a href="#rid22">22-24</a>]. Older studies suggested these PVCs were associated with a twofold increase in myocardial infarction or death in males [<a href="#rid22">22,24</a>]. A newer study in a Taiwanese population suggested a smaller magnitude of effect; multiform PVCs were associated with a 20 percent increased risk of mortality and 10 percent increased risk for hospitalization [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H1012569951"><span class="h2">Underlying or associated cardiac disease</span><span class="headingEndMark"> — </span>PVCs can be the first manifestation of cardiac disease, including coronary artery disease, cardiomyopathy, and inherited arrhythmia syndromes (eg, long QT syndrome, arrhythmogenic right ventricular cardiomyopathy).</p><p>In addition, patients with a high PVC burden can develop a cardiomyopathy. In some people with inherited arrythmia syndromes, PVCs can trigger ventricular tachyarrhythmia. (See  <a class="medical medical_review" href="/z/d/html/1009.html" rel="external">"Congenital long QT syndrome: Pathophysiology and genetics", section on 'Triggered activity'</a> and  <a class="medical medical_review" href="/z/d/html/1020.html" rel="external">"Brugada syndrome: Epidemiology and pathogenesis", section on 'Ventricular arrhythmias and phase 2 reentry'</a> and  <a class="medical medical_review" href="/z/d/html/994.html" rel="external">"Premature ventricular complexes: Clinical presentation and diagnostic evaluation", section on 'R-on-T phenomenon'</a>.)</p><p>If a patient has a left ventricular ejection fraction (LVEF) &lt;50 percent (regardless of symptoms) and a high PVC burden, the LVEF reduction is assumed to be related to frequent PVCs (also called PVC-induced cardiomyopathy [<a href="#rid25">25,26</a>]). In one series of 245 patients with PVC-induced cardiomyopathy, independent predictors for development of PVC-induced cardiomyopathy were male sex, high PVC burden, lack of symptoms, and epicardial PVC origin [<a href="#rid27">27</a>]. (See <a class="local">'Premature ventricular complex cardiomyopathy'</a> below.)</p><p class="headingAnchor" id="H2330869149"><span class="h3">Evaluation in most patients</span><span class="headingEndMark"> — </span>In order to assess PVC burden and the presence of structural heart disease, all patients should undergo:</p><p class="bulletIndent1"><span class="glyph">●</span>A 12-lead electrocardiogram (ECG).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Twenty-four-hour Holter monitoring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An echocardiogram should be performed if there are high-risk symptoms, frequent PVCs, or if there is any suspicion of underlying or new structural heart disease (including PVC cardiomyopathy) and/or high-risk information from other risk assessments such as abnormal 12-lead ECG or family history of heart disease and especially of sudden cardiac death. (See <a class="local">'Symptoms'</a> above and <a class="local">'Family history'</a> above and <a class="local">'Premature ventricular complex burden'</a> above and <a class="local">'Premature ventricular complex characteristics'</a> above.) </p><p></p><p>When ambulatory ECG monitoring is indicated, a monitoring period of 24 to 48 hours is typically sufficient to identify PVCs and quantify the overall PVC burden. A variety of ambulatory ECG monitoring techniques are available, but for most patients Holter monitoring or patch monitoring will be the preferred approach. (See  <a class="medical medical_review" href="/z/d/html/958.html" rel="external">"Ambulatory ECG monitoring"</a>.)</p><p class="headingAnchor" id="H3400386407"><span class="h3">Further testing in selected patients</span><span class="headingEndMark"> — </span>Specific symptoms and/or high-risk features are reasons to get further cardiac testing.</p><p>If obstructive coronary disease is suspected (on the basis of symptoms or risk factors), or the PVCs are effort related, the patient should also undergo:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise stress testing</strong> – Among patients with effort-related symptoms and who are suspected to have obstructive coronary disease, exercise stress testing can evaluate ischemia [<a href="#rid28">28</a>] and provide useful prognostic information. (See  <a class="medical medical_review" href="/z/d/html/1548.html" rel="external">"Prognostic features of stress testing in patients with known or suspected coronary disease"</a>.)</p><p></p><p class="bulletIndent1">PVCs occurring during exercise may be secondary to underlying ischemia or could represent adrenergic or catecholamine-sensitive arrhythmias (eg, inherited channelopathies) [<a href="#rid29">29</a>]. For patients whose PVCs are induced by exercise, exercise testing in conjunction with ambulatory monitoring can be used to assess the effectiveness of antiarrhythmic drug treatment. </p><p></p><p class="bulletIndent1">For patients with exercise-related PVCs, further cardiac testing for underlying cardiovascular disease should be undertaken that may include additional cardiac tests, such as stress testing with imaging, cardiac magnetic resonance imaging (CMR), and electrophysiology testing [<a href="#rid30">30-32</a>]. </p><p></p><p class="bulletIndent1">More commonly, however, PVCs are suppressed during exercise and reemerge in the ensuing recovery period. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac</strong> <strong>magnetic resonance imaging</strong> – Selected patients (ie, those with high-risk PVC features, a family history of sudden death or cardiomyopathy, and/or cardiomyopathy of uncertain etiology) may require CMR [<a href="#rid33">33</a>]. CMR can be particularly useful in diagnosing hypertrophic cardiomyopathy, cardiac sarcoid, arrhythmogenic right ventricular cardiomyopathy, and amyloid cardiomyopathy. CMR is generally obtained if these conditions are suspected based on baseline ECG and/or echocardiogram characteristics, family history, and exercise history. We do not routinely use CMR imaging for all patients with frequent PVCs due to limited availability of this test, high cost, lack of expertise in cardiac MRI imaging, and the lack of prospective randomized trials demonstrating that a CMR-based strategy improves outcomes, including mortality. CMR is used selectively and can be center dependent, based on local availability and expertise. Screening with CMR may be useful before further invasive electrophysiology assessment and therapeutic decision-making are undertaken. For instance, CMR may play a role in evaluating need for implantable cardioverter-defibrillator (ICD) in patients with PVC cardiomyopathy. (See <a class="local">'Implantable cardioverter-defibrillator'</a> below.)</p><p></p><p class="bulletIndent1">Observational studies in patients with frequent PVCs have shown that myocardial abnormalities on CMR are commonly seen (ie, in 15 to 35 percent of such patients) and are associated with adverse cardiac outcomes [<a href="#rid34">34-36</a>]. Among an international cohort of 518 patients (mean age 44 years) with frequent (&gt;1000/24 hours) PVCs and otherwise negative diagnostic work-up, myocardial abnormalities were found in 85 patients (16 percent) [<a href="#rid34">34</a>]. In a single-center observational study, 255 patients with frequent PVCs (&gt;5 percent per 24 hours) who had a contrast-enhanced CMR for work-up of PVCs were followed for the composite outcome (mortality, ventricular fibrillation, sustained ventricular tachycardia, or reduction in left ventricular ejection fraction of ≥10 percent) [<a href="#rid35">35</a>]. Thirty-five percent of patients had a myocardial abnormality on CMR, and the composite outcome occurred in 5.9 percent. After a median follow-up of 36 months, the incidence of the composite outcome was higher among patients with myocardial abnormalities versus a normal CMR (20 versus 3.6 percent; hazard ratio 4.35, 95% CI 1.34-14.15). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrophysiology testing</strong> – Electrophysiology testing is used only in selected patients with higher-risk PVC features as a risk stratification tool to guide therapy or in patients undergoing catheter ablation procedure (ie, as treatment for frequent symptomatic PVCs refractory to medical therapy or in whom the PVCs have resulted in cardiomyopathy). (See  <a class="medical medical_review" href="/z/d/html/980.html" rel="external">"Invasive diagnostic cardiac electrophysiology studies"</a> and <a class="local">'Implantable cardioverter-defibrillator'</a> below.) </p><p></p><p class="headingAnchor" id="H3492582627"><span class="h1">MANAGE TRIGGERS AND RISK FACTORS</span><span class="headingEndMark"> — </span>Prior to initiating therapy, correctable causes or triggers should be identified and, where possible, corrected  (<a class="graphic graphic_table graphicRef138370" href="/z/d/graphic/138370.html" rel="external">table 1</a>). </p><p>Patients with hypertension often have PVCs, and if there is left ventricular hypertrophy, outcomes are often worse. These patients should have their blood pressure controlled, preferably with a beta blocker and/or an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker, and receive treatment for concurrent left ventricular dysfunction/heart failure if present. Efforts should be made to avoid hypokalemia, which can result from the diuretic class of antihypertensive agents [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a> and  <a class="medical medical_review" href="/z/d/html/994.html" rel="external">"Premature ventricular complexes: Clinical presentation and diagnostic evaluation", section on 'Associated conditions'</a>.)</p><p class="headingAnchor" id="H3660259048"><span class="h1">MANAGEMENT OF HIGH-RISK PATIENTS</span><span class="headingEndMark"> — </span>High-risk patients have any of the following conditions: high (&gt;10 to 15 percent) PVC burden, PVC-induced cardiomyopathy, preexisting cardiac structural or electrical conduction system disease, history of syncope, and abnormalities on cardiac magnetic resonance (CMR) imaging even in the presence of a normal LVEF [<a href="#rid34">34,38,39</a>]. </p><p>Management in these patients is required to reverse or reduce the risk of developing a cardiomyopathy and to reduce the risk of ventricular arrhythmias and sudden cardiac death  (<a class="graphic graphic_algorithm graphicRef138294" href="/z/d/graphic/138294.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H1106544931"><span class="h2">Premature ventricular complex cardiomyopathy</span><span class="headingEndMark"> — </span>If a patient has an LVEF &lt;50 percent (regardless of symptoms), and a high PVC burden, the LVEF reduction is assumed to be related to frequent PVCs, and the diagnosis is PVC-induced cardiomyopathy [<a href="#rid25">25,26</a>]. (See  <a class="medical medical_review" href="/z/d/html/994.html" rel="external">"Premature ventricular complexes: Clinical presentation and diagnostic evaluation", section on 'PVC-induced cardiomyopathy'</a> and <a class="local">'Underlying or associated cardiac disease'</a> above and <a class="local">'Premature ventricular complex burden'</a> above.)</p><p>In such patients, treatment is aimed towards reducing PVC burden, which can in turn avert or reverse the cardiomyopathy. Even patients who already have an implantable cardioverter-defibrillator (ICD) benefit from PVC reduction and ablation.</p><p>Some patients with PVC-induced cardiomyopathy will exhibit signs and symptoms of heart failure that may require treatment with heart failure medications. However, the definitive treatment is to suppress or ablate the PVCs. (See  <a class="medical medical_review" href="/z/d/html/1062.html" rel="external">"Arrhythmia-induced cardiomyopathy", section on 'Frequent ventricular ectopy'</a> and  <a class="medical medical_review" href="/z/d/html/994.html" rel="external">"Premature ventricular complexes: Clinical presentation and diagnostic evaluation", section on 'PVC-induced cardiomyopathy'</a>.)</p><p>Calcium channel blockers should generally be avoided in patients with cardiomyopathy. (See  <a class="medical medical_review" href="/z/d/html/3499.html" rel="external">"Drugs that should be avoided or used with caution in patients with heart failure", section on 'Calcium channel blockers'</a>.)</p><p class="headingAnchor" id="H3234175888"><span class="h3">Beta blockers</span><span class="headingEndMark"> — </span>The first-line therapy to reduce PVC burden is beta blockers. An exception may be those with heart failure who may proceed directly to catheter ablation. </p><p>Commonly used beta blockers to treat PVCs include <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> and <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">carvedilol</a>. Typical starting doses, alternatives, and maximum dosages for PVC treatment are given in a table  (<a class="graphic graphic_table graphicRef138406" href="/z/d/graphic/138406.html" rel="external">table 2</a>). Once given, the patient should be monitored for a reduction in symptoms that correspond with a reduction in PVCs, titrating the medication as necessary. Repeat ambulatory ECG monitoring is typically obtained after three months of treatment to determine if the patient has responded to beta blockers. If symptoms and PVC burden have been reduced and are not high, the beta blocker should be continued.</p><p>If after one month of maximal beta blocker therapy there is no symptom relief or decrease in PVC burden, a catheter ablation is usually considered (especially if PVCs are monomorphic, making them more amenable to ablation). Alternatively, some patients are treated with antiarrhythmic drugs. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy of beta blockers </strong>–<strong> </strong>Beta blockers are effective at reducing PVC symptoms. This is because beta blockers reduce the post-extrasystolic potentiation via the Starling mechanism (increased inotropy related to the increased stroke volume) associated with the PVC. Beta blockers can also prevent PVC recurrence.<strong> </strong>However, it should be recognized that they have no direct effects on the ventricular myocardium. Therefore, beta blockers are most likely to suppress PVCs that result from excess sympathetic stimulation or are catecholamine sensitive. </p><p></p><p>In an observational study, beta blockers were reported to reduce PVC burden in one-third of patients taking them [<a href="#rid40">40</a>]. Similar findings (a 21 to 36 percent PVC reduction) were reported by other studies [<a href="#rid41">41,42</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weaning</strong> – Sometimes, a patient will prefer to stop the beta blocker after symptom relief is achieved. In this case, one can try to wean the beta blocker after 6 to 12 months of medication treatment. The dose can be gradually reduced and a 24-hour Holter recording can be repeated periodically. It is preferable to keep the patient on at least a low-dose beta blocker if they are willing, as this may prevent PVC reoccurrence. (See <a class="local">'Premature ventricular complex burden'</a> above.) </p><p></p><p class="headingAnchor" id="H3218155466"><span class="h3">Catheter ablation</span><span class="headingEndMark"> — </span>Catheter ablation is an effective option  (<a class="graphic graphic_algorithm graphicRef126128" href="/z/d/graphic/126128.html" rel="external">algorithm 2</a>) to reduce or eliminate PVCs in patients who do not respond to beta blocker therapy [<a href="#rid41">41,43-49</a>] and may be first-line treatment in those with heart failure. In a multicenter study of 1185 patients undergoing PVC ablation, 85 percent did not require the use of antiarrhythmic medications at two years following ablation [<a href="#rid27">27</a>]. </p><p>In patients with PVC-induced cardiomyopathy, PVC ablation can lead to left ventricular function recovery. In a multicenter study of 245 patients with PVC-induced cardiomyopathy who underwent ablation, the LVEF increased from 38 to 50 percent after ablation [<a href="#rid27">27</a>]. </p><p>The decision to recommend radiofrequency catheter ablation versus antiarrhythmic therapy in a particular patient will depend on clinical factors (ie, predictors of procedural success) and on patient preference. Some patients will not want to undergo an invasive catheter ablation procedure. Not all centers have catheter ablation expertise. Reasonable attempts should be made to refer appropriate patients to centers with catheter ablation expertise.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Predictors of procedural success </strong>–<strong> </strong>Clinical variables that identify patients most likely to respond to catheter ablation and/or less likely to experience complications include [<a href="#rid37">37</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unifocal PVCs.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High PVC burden. (See <a class="local">'Premature ventricular complex burden'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Right ventricular outflow tract (RVOT) origin. PVCs of right ventricular origin (left bundle branch block inferior axis) will have left bundle branch inferior axis morphology on 12-lead ECG  (<a class="graphic graphic_waveform graphicRef139349" href="/z/d/graphic/139349.html" rel="external">waveform 5</a>). For such patients, we have a lower threshold to do catheter ablation, as ablation of PVCs in the right ventricle requires only venous access. In contrast, PVCs arising in the LV outflow tract or LV require retrograde aortic or transeptal access and have a higher associated procedural risk. In a 2014 meta-analysis of small nonrandomized studies of patients with idiopathic PVCs originating from the RVOT, catheter ablation was associated with a reduction in PVC burden (97 percent mean reduction) along with an improvement in LVEF (mean increase 10 percent) [<a href="#rid50">50</a>]. Heterogeneity across studies limited the certainty of these effect estimates.</p><p></p><p>The majority of patients with PVC-induced LV dysfunction have a recovery of LV function within four months. In some patients, recovery of LV function may take longer; an epicardial origin of PVCs and/or a significantly longer PVC-QRS width are more often present in patients with delayed recovery of LV function than in patients with early recovery of LV function. In a study of 75 patients with frequent idiopathic PVCs and PVC-induced cardiomyopathy submitted to successful PVC ablation, the majority (68 percent) had a recovery of LV function within four months [<a href="#rid48">48</a>]. Patients with delayed recovery of LV function were more likely to have epicardial origin of PVCs (54 versus 4 percent) and longer PVC-QRS width (170±21 versus 159±16 ms) compared with those with an earlier recovery. Similarly, in a study of 114 patients, mean PVC-QRS was 173 ms for those with irreversible LV dysfunction versus 158 ms for those with reversible LV dysfunction (odds ratio 5) [<a href="#rid51">51</a>]. </p><p>Predictors of ablation failure include multiple PVC morphologies, epicardial or papillary muscle origins, and decreased/short earliest local activation time [<a href="#rid27">27,52</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PVC ablation complications </strong>–<strong> </strong>Regardless of whether venous or arterial access is needed, vascular complications are a potential risk of the procedure. Ablation of PVCs originating in the LV require arterial access, and therefore, circulatory complications of stroke, myocardial infarction, and mitral or aortic valve damage can occur. Myocardial perforation and cardiac tamponade or coronary artery injury are potentially lethal complications [<a href="#rid53">53,54</a>]. </p><p></p><p class="bulletIndent1">In a study of 1185 patients undergoing catheter ablation for PVCs, the major complication rate was 2.4 percent, with the most common complications related to vascular access [<a href="#rid27">27</a>]. Nine patients (0.8 percent) had pericardial tamponade requiring pericardiocentesis, and a single patient experienced permanent atrioventricular block. No patients died or experienced stroke. In another study, among 1231 patients undergoing PVC ablation, the overall complication rate was 2.7 percent, with cardiac tamponade being the most common complication (27 percent of all complications or an overall rate of 0.7 percent) [<a href="#rid54">54</a>]. Two ablation-related deaths occurred; one patient died from coronary artery injury during the procedure, and the other died from infectious endocarditis. Location (LV and epicardium) was the main predictor of complications, with RVOT predicting fewer complications. Potential risks of catheter ablation are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1007.html" rel="external">"Overview of catheter ablation of cardiac arrhythmias", section on 'Complications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Expected timeframe for recovery of LVEF </strong>–<strong> </strong>Repeat cardiac monitoring should be performed post-procedure at approximately three months to assess PVC burden. Also, a repeat echocardiogram should be performed three months after the PVC ablation to assess for LV function recovery. </p><p></p><p class="bulletIndent1">Most patients experience complete LVEF recovery after three to six months post-ablation [<a href="#rid55">55</a>]. In about one-third of patients, recovery is delayed and can take up to three to four years [<a href="#rid48">48</a>]. Predictors of delayed recovery included epicardial-origin PVCs [<a href="#rid27">27</a>] and increased intrinsic QRS duration [<a href="#rid56">56</a>]. </p><p></p><p class="headingAnchor" id="H2249000842"><span class="h3">Antiarrhythmic therapy</span><span class="headingEndMark"> — </span>If a patient is not an optimal candidate for, or prefers not to have, an invasive ablation procedure, an antiarrhythmic agent can be tried. </p><p>In patients with structural heart disease, including those with PVC cardiomyopathy, there are limited safe and efficacious antiarrhythmic drugs [<a href="#rid37">37,50</a>].</p><p>Preferred agents for patients with underlying heart disease are <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> and <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a>: </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a><strong> </strong>–<strong> </strong>Amiodarone is the least proarrhythmic agent in patients with structural heart disease, although there are substantial risks of organ toxicities with long-term use. </p><p></p><p class="bulletIndent1">Trials of <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> use in patients with PVCs and prior myocardial infarction or heart failure have demonstrated a reduction in PVCs and in arrhythmic mortality (6.9 versus 4.5 percent; relative risk 0.49; 95% CI 0.05-0.72) but not overall mortality  (<a class="graphic graphic_figure graphicRef67684" href="/z/d/graphic/67684.html" rel="external">figure 1</a>) [<a href="#rid57">57</a>]. However, routine amiodarone therapy in asymptomatic patients is not recommended because of the limited benefit and potential side effects [<a href="#rid57">57-59</a>]. </p><p></p><p class="bulletIndent1">Oral loading doses of 400 to 1200 mg/day in divided doses (up to a total loading dose of 6 to 10 grams) can be used. The usual maintenance dose should be the lowest effective dose; this is usually 200 mg daily but can be as low as 100 mg daily. (See  <a class="medical medical_review" href="/z/d/html/926.html" rel="external">"Amiodarone: Clinical uses", section on 'Amiodarone for ventricular arrhythmias'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">Ranolazine</a><strong> </strong>–<strong> </strong>Ranolazine<strong>, </strong>an oral antianginal medication that has I<sub>Na</sub>-<sub> </sub>and IKr-blocking properties, is approved for patients with chronic stable angina. Observational studies [<a href="#rid60">60</a>] and case reports/series [<a href="#rid61">61-63</a>] suggest that ranolazine may be a safe and effective treatment for PVCs; however, no randomized trials have been performed to confirm these results. In one cohort of 59 patients with ventricular ectopy with or without cardiac disease, ranolazine reduced PVCs by 71 percent (from 13,329 to 3837 per day) [<a href="#rid60">60</a>]. Ventricular bigeminy and couplets were each reduced by 80 percent, and ventricular tachycardia was reduced by 90 percent. </p><p></p><p class="bulletIndent1">Safety and efficacy of <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> for ventricular tachycardia were studied in the MERLIN-TIMI 36 trial (ventricular tachycardia lasting ≥3 beats, 52 versus 61 percent; relative risk 0.86, 95% CI 0.82-0.90) [<a href="#rid64">64</a>] without causing significant proarrhythmia [<a href="#rid65">65</a>]. </p><p></p><p class="bulletIndent1">Starting dose is 500 mg orally twice daily; maximum daily dose 1000 mg twice daily.</p><p></p><p>Class IC drugs may be proarrhythmic in patients with coronary artery disease and/or significant myocardial dysfunction; therefore, they should not be used in these patients [<a href="#rid66">66,67</a>]. In patients with a prior myocardial infarction, the use of <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a> and other class IC antiarrhythmic drugs  (<a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">table 3</a>) for PVCs has been associated with increased mortality due to proarrhythmia  (<a class="graphic graphic_figure graphicRef59975" href="/z/d/graphic/59975.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef71934" href="/z/d/graphic/71934.html" rel="external">figure 3</a>) [<a href="#rid66">66,67</a>]. Flecainide and <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a> (class IC antiarrhythmic drugs  (<a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">table 3</a>)) have been successfully used in patients with suspected PVC-induced cardiomyopathy who have failed previous catheter ablation attempts [<a href="#rid68">68</a>], but they should not be generally used in this setting due to safety concerns. The use of these drugs in lower-risk patients is discussed below. (See <a class="local">'Subsequent therapy'</a> below.)</p><p class="headingAnchor" id="H3165348044"><span class="h3">Implantable cardioverter-defibrillator</span><span class="headingEndMark"> — </span>In patients with PVC-induced cardiomyopathy and very low LVEF (&lt;35 percent) that would otherwise meet primary prevention criteria for an ICD, elimination of the PVCs can generally restore LV function and obviate the need for ICD implantation [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/z/d/html/921.html" rel="external">"Implantable cardioverter-defibrillators: Overview of indications, components, and functions", section on 'Primary prevention'</a>.) </p><p>However, when the etiology of nonischemic cardiomyopathy is not clear, which can be the case before PVCs are eliminated and the LVEF normalizes, there remains a concern about the risk of sudden cardiac death. Thus, preprocedural CMR followed by an electrophysiology study with programmed ventricular stimulation, particularly in CMR-positive patients, may be considered [<a href="#rid30">30</a>]. In the absence of CMR-defined myocardial fibrosis/scarring and/or inducible ventricular tachycardia during an electrophysiology study, one can wait for improvement in LVEF following PVC elimination, withholding the ICD and reevaluating the patient within six months of ablation. (See  <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">"Determining the etiology and severity of heart failure or cardiomyopathy", section on 'Cardiovascular magnetic resonance'</a> and  <a class="medical medical_review" href="/z/d/html/994.html" rel="external">"Premature ventricular complexes: Clinical presentation and diagnostic evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/980.html" rel="external">"Invasive diagnostic cardiac electrophysiology studies"</a>.)</p><p class="headingAnchor" id="H2317213880"><span class="h2">Preexisting cardiac disease</span><span class="headingEndMark"> — </span>Patients with coronary artery disease, cardiomyopathy, or electrical conduction system disease who have PVCs are considered high risk. High-risk PVC characteristics, including morphology and origin, are discussed above. (See <a class="local">'Premature ventricular complex characteristics'</a> above.) </p><p>For patients with underlying structural heart disease, it is important to reduce the PVC burden if it is high (ie, &gt;15 percent or 15,000 PVCs/day) in order to lower the risk of developing PVC-induced cardiomyopathy.</p><p>The first-line therapy for these patients is to reduce PVC burden with beta blockers. If after two to four weeks of beta blocker therapy, there is no decrease in PVC burden and/or there is a persistent reduction in LVEF, catheter ablation is usually considered next [<a href="#rid27">27,37,41,43-50</a>]. (See <a class="local">'Catheter ablation'</a> above.) </p><p>Generally, treating the underlying condition often improves and can reduce PVC burden. For an inherited cardiomyopathy or arrythmia syndrome, referral to a genetic counselor is also appropriate. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure </strong>– Patients with dilated cardiomyopathy or heart failure have a reported 70 to 95 percent prevalence of PVCs [<a href="#rid70">70</a>]. The evaluation and management of PVCs in such patients are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/968.html" rel="external">"Ventricular arrhythmias: Overview in patients with heart failure and cardiomyopathy"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coronary artery disease</strong> – The management of PVCs differs in patients with acute and chronic coronary syndrome.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute coronary syndrome</strong> – For persons with PVCs in the setting of acute coronary syndromes, the best antiarrhythmic approach is the use of antiischemic therapies (reperfusion/revascularization) combined with a beta blocker. As mentioned, treatment with <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> may significantly lower the incidence of ventricular arrhythmias in patients with a non-ST-elevation acute coronary syndrome, as shown in MERLIN-TIMI 36 trial [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/z/d/html/184.html" rel="external">"Initial evaluation and management of suspected acute coronary syndrome (myocardial infarction, unstable angina) in the emergency department", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/118996.html" rel="external">"Ventricular arrhythmias during acute myocardial infarction: Prevention and treatment", section on 'Ventricular premature beats'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic coronary syndrome</strong> – In patients who have had past myocardial infarctions, PVCs, particularly if frequent (more than 10 per hour) or complex (ie, repetitive forms, primarily nonsustained ventricular tachycardia), appear to be associated with a worse prognosis. </p><p></p><p class="bulletIndent2">Most patients with a prior myocardial infarction will be taking a beta blocker as part of standard therapy for their underlying disease, which may be associated with a reduction in PVCs [<a href="#rid71">71,72</a>]. (See  <a class="medical medical_review" href="/z/d/html/1466.html" rel="external">"Beta blockers in the management of chronic coronary syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Beta blocker'</a>.)</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a> is the preferred antiarrhythmic drug in patients with symptomatic PVCs despite beta blocker therapy. Attempted suppression of PVCs with class IC antiarrhythmic drugs in patients with coronary artery disease has been associated with increased mortality  (<a class="graphic graphic_figure graphicRef59975" href="/z/d/graphic/59975.html" rel="external">figure 2</a>). (See <a class="local">'Antiarrhythmic therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/926.html" rel="external">"Amiodarone: Clinical uses", section on 'Amiodarone for ventricular arrhythmias'</a>.) </p><p></p><p class="bulletIndent2">In cases of complex and/or symptomatic ventricular arrhythmia, an electrophysiology study with programmed ventricular stimulation may better guide therapy. In patients with inducible sustained ventricular tachycardia, an ICD will be needed [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/z/d/html/921.html" rel="external">"Implantable cardioverter-defibrillators: Overview of indications, components, and functions", section on 'Secondary prevention'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with cardiac resynchronization therapy (CRT) </strong>– Patients with a CRT device need to have effective biventricular pacing greater than 98 percent of all ventricular beats in order to have a mortality reduction [<a href="#rid74">74</a>]. Frequent PVCs compromise effective biventricular pacing and diminish clinical response to CRT [<a href="#rid75">75</a>]. Hence, a more aggressive approach to suppress PVCs is recommended in these patients. (See  <a class="medical medical_review" href="/z/d/html/921.html" rel="external">"Implantable cardioverter-defibrillators: Overview of indications, components, and functions"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertension</strong> – This is discussed elsewhere. (See <a class="local">'Manage triggers and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long QT syndrome</strong> – This is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/988.html" rel="external">"Congenital long QT syndrome: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Brugada syndrome</strong> – This is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/106760.html" rel="external">"Brugada syndrome or pattern: Management and approach to screening of relatives"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertrophic cardiomyopathy</strong> – This is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/119625.html" rel="external">"Hypertrophic cardiomyopathy: Management of ventricular arrhythmias and sudden cardiac death risk"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arrhythmogenic right ventricular cardiomyopathy</strong> – This is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4932.html" rel="external">"Arrhythmogenic right ventricular cardiomyopathy: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac sarcoidosis </strong>– This is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amyloid cardiomyopathy </strong>– This is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/85952.html" rel="external">"Cardiac amyloidosis: Treatment and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H1699284054"><span class="h1">MANAGEMENT OF LOW-RISK PATIENTS</span><span class="headingEndMark"> — </span>Low-risk patients are those in whom cardiomyopathy and/or inherited arrythmia syndrome has been reasonably excluded. </p><p>Our approach to treatment in low-risk patients differs according to whether there are significant PVC-related symptoms. Specific PVC-related symptoms are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/994.html" rel="external">"Premature ventricular complexes: Clinical presentation and diagnostic evaluation", section on 'Symptoms'</a>.)</p><p class="headingAnchor" id="H66772678"><span class="h2">Asymptomatic patients with low premature ventricular complex burden</span><span class="headingEndMark"> — </span>For patients with a low burden of PVCs (&lt;1 percent or 1000 PVCs/day), no underlying apparent structural heart disease, and no symptoms, neither medical therapy nor catheter ablation are required; observation and reassurance along with eliminating possible triggers are appropriate  (<a class="graphic graphic_algorithm graphicRef126128" href="/z/d/graphic/126128.html" rel="external">algorithm 2</a> and <a class="graphic graphic_algorithm graphicRef138293" href="/z/d/graphic/138293.html" rel="external">algorithm 3</a>) [<a href="#rid49">49</a>]. </p><p>While PVCs have been associated with increased risk of cardiovascular death and other adverse outcomes, there is no clear evidence that PVC suppression or elimination with beta blockers, non-dihydropyridine calcium channel blockers, antiarrhythmic drugs, or catheter ablation improves overall survival in patients who have no symptoms, no heart disease, and no sustained ventricular arrhythmias. </p><p class="headingAnchor" id="H483363019"><span class="h2">Patient with symptoms and/or high premature ventricular complex burden</span><span class="headingEndMark"> — </span>Most low-risk patients with significant symptoms from their PVCs will require medical therapy or ablation in an effort to reduce or eliminate symptoms  (<a class="graphic graphic_algorithm graphicRef126128" href="/z/d/graphic/126128.html" rel="external">algorithm 2</a> and <a class="graphic graphic_algorithm graphicRef138293" href="/z/d/graphic/138293.html" rel="external">algorithm 3</a>). Patients with high PVC burden (&gt;15 percent or 15,000 PVCs/day) also benefit from treatment even in the absence of bothersome symptoms to lower their risk of PVC-induced cardiomyopathy.<em> </em></p><p>PVC-induced cardiomyopathy typically takes several months or a few years to develop. In a study of 240 patients referred for PVC ablation, symptom duration of 30 to 60 months, as well as symptom duration &gt;60 months, independently predicted impaired LV function (odds ratio 4.0, 95% CI 1.1-14.4 and 20.1, 95% CI 6.3-64.1, respectively) [<a href="#rid76">76</a>].</p><p>In a low-risk patient who has more noticeable symptoms in a quiet environment, such as at night while lying in bed, counseling them to move around and increase their heart rate may alleviate symptoms and provide reassurance to the patient. </p><p>The decision to recommend antiarrhythmic medication or radiofrequency catheter ablation in a particular patient will depend on many clinical factors and also on patient preference. Some patients will not want to undergo an invasive catheter ablation procedure. Potential risks of the catheter ablation are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1007.html" rel="external">"Overview of catheter ablation of cardiac arrhythmias", section on 'Complications'</a>.)</p><p class="headingAnchor" id="H3897908816"><span class="h3">Initial therapy</span><span class="headingEndMark"> — </span>Prior to initiating therapy, correctable causes or triggers should be identified and corrected  (<a class="graphic graphic_table graphicRef138370" href="/z/d/graphic/138370.html" rel="external">table 1</a>).  </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta blockers </strong>– For low-risk patients with symptomatic and/or a high burden of PVCs, we suggest first-line therapy with a beta blocker. (See <a class="local">'Beta blockers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-dihydropyridine calcium channel blockers</strong> – In patients without a reduced LVEF, a non-dihydropyridine calcium channel blocker can be substituted if beta blockers are not tolerated or are not successful in reducing symptoms. A table lists specific agents with dosages  (<a class="graphic graphic_table graphicRef138406" href="/z/d/graphic/138406.html" rel="external">table 2</a>). </p><p></p><p class="bulletIndent1">Non-dihydropyridine calcium channel blockers may be particularly effective in patients without apparent structural heart disease when PVCs are often due to triggered activity of calcium-dependent mechanisms. One example of this is PVCs of fascicular origin (relatively narrow QRS, right bundle branch block-like, left axis deviation)  (<a class="graphic graphic_waveform graphicRef139331" href="/z/d/graphic/139331.html" rel="external">waveform 6</a>). Calcium channel blockers may also be preferred to beta blockers if hypertension treatment is needed.</p><p></p><p class="bulletIndent2">Patients should be evaluated for PVCs burden with periodic examinations and continuous ECG monitoring, usually for 24 to 48 hours. (See  <a class="medical medical_review" href="/z/d/html/994.html" rel="external">"Premature ventricular complexes: Clinical presentation and diagnostic evaluation", section on 'Ambulatory monitoring'</a>.)</p><p></p><p class="bulletIndent2">If symptoms and PVC burden have been reduced and are not high, treatment should be continued. If a patient prefers to stop or reduce their medications, a trial of weaning and/or stopping may be done after 6 to 12 months. (See <a class="local">'Premature ventricular complex burden'</a> above and <a class="local">'Beta blockers'</a> above.) </p><p></p><p>A prospective cohort study of 100 untreated adult patients (mean age 51.8 years, 57 percent female) with a median PVC burden of 18.4 percent showed that reduction to &lt;1 percent of PVCs occurred in 44 percent at a median follow-up of 15.4 months. Recurrence was uncommon (9.1 percent) [<a href="#rid77">77</a>]. Hence, the authors suggested that a strategy of active surveillance may be appropriate for the majority of patients with frequent idiopathic PVCs in association with preserved LVEF. One may extrapolate from these studies that in certain patients who respond to medical treatment, one may trial them off antiarrhythmic drug therapy, possibly at one to two years, and closely observe for arrhythmia recurrences. </p><p class="headingAnchor" id="H49659458"><span class="h3">Subsequent therapy</span><span class="headingEndMark"> — </span>For patients with ongoing PVC-related symptoms and/or high burden following initial medical therapy with beta blockers and/or non-dihydropyridine calcium channel blockers, or for those who do not tolerate medical therapy due to adverse effects, antiarrhythmic medications or catheter ablation are each reasonable next steps.</p><p>In patients without structural heart disease or coronary artery disease, it is reasonable to start a class 1C antiarrhythmic rather than to pursue catheter ablation if one or more of the following are present:</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple PVC morphologies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A low frequency of PVCs (&lt;3 percent or 500 PVCs/day).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients are deemed to be high-risk candidates for catheter ablation, such as those with challenging PVC foci locations that might limit a successful procedure (eg, epicardium, LV summit, intramural site, papillary muscles, and a para-Hisian location) [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A strong patient preference to avoid catheter ablation.</p><p></p><p class="bulletIndent2">The use of antiarrhythmic drugs (eg, <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a> and other class IC antiarrhythmic drugs)  (<a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">table 3</a>) for PVCs is an off-label use. Whereas proarrhythmia with these drugs is of concern in patients with structural heart disease, there is little to no concern in patients without underlying heart disease [<a href="#rid79">79</a>]. Importantly, class IC antiarrhythmic agents should not be used to treat patients with PVC-induced cardiomyopathy and LV dysfunction due to grave concerns for proarrhythmia [<a href="#rid66">66,80</a>]. Nevertheless, IC agents have been used in such patients with favorable results. However, these agents should only be prescribed in patients who have ICDs to treat life-threatening ventricular arrythmias [<a href="#rid68">68</a>]. </p><p></p><p class="bulletIndent2">Typical antiarrhythmic options among patients without apparent structural heart disease include:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">Flecainide</a>, starting dose 50 to 100 mg orally twice daily; maximum daily dose 150 mg twice daily (although doses higher than 100 mg twice daily are rarely used).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">Propafenone</a> 150 mg three times daily; maximum daily dose 300 mg three times daily.</p><p></p><p class="bulletIndent2">In one observational study of 120 patients with frequent PVCs without structural heart disease, antiarrhythmic medications had superior effectiveness in PVC reduction as compared with beta blockers and calcium channel blockers and conservative therapy [<a href="#rid40">40</a>]. Median initial PVC burden ranged from 16 to 21 percent. The median relative reduction of PVCs in the conservative therapy, beta blockers/calcium channel blockers, and antiarrhythmic medication cohorts was 33, 31, and 81 percent, respectively. PVC reduction to &lt;1 percent was similar across these groups at 35, 17, 33 percent, respectively. Four patients (3 percent) developed LV dysfunction: One patient was on conservative therapy, two were on a <a class="drug drug_general" data-topicid="9158" href="/z/d/drug information/9158.html" rel="external">bisoprolol</a>, and one was on <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a>. Rates of adverse drug reactions and medication discontinuation were similar between groups, with no serious adverse events noted.</p><p></p><p class="bulletIndent2">If a patient remains symptomatic and/or has a high PVC burden, catheter ablation should be pursued next.</p><p></p><p class="headingAnchor" id="H734591512"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The presence of PVCs should alert the clinician to potential coexistent cardiac disease, which may require additional clinical assessment or therapy. In patients without a history of cardiac disease, PVCs are associated with increased mortality. However, prophylactic treatment of asymptomatic PVCs in patients without cardiomyopathy has not been shown to improve mortality. An important caveat pertains to patients with potentially problematic PVCs. (See <a class="local">'Premature ventricular complex characteristics'</a> above.)</p><p class="headingAnchor" id="H3615381516"><span class="h2">No apparent heart disease</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mortality </strong>– Data are mixed as to whether the presence of PVCs in patients with apparently normal hearts is associated with increased mortality. In a meta-analysis of five prospective cohort studies (3629 persons) without apparent heart disease, the presence of PVCs was not associated with all-cause mortality (odds ratio 1.34, 95% CI 0.85-2.12) [<a href="#rid81">81</a>]. However, only one study used advanced testing (ie, echocardiography or stress testing) to exclude underlying structural heart disease. In a Taiwanese cohort of 5778 persons, PVC frequency &gt;12 beats per day was associated with mortality (hazard ratio 1.4, 95% CI 1.28-1.59) [<a href="#rid82">82</a>]. Regarding PVC morphology, an observational study indicated that among 3351 individuals with apparently normal hearts, those with multiform PVCs had an increased incidence of mortality (HR 1.6, 95% CI 1.32-2.03) over a mean follow-up period of 10 years [<a href="#rid17">17</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reduction in LVEF and heart failure </strong>– A greater frequency of PVCs has been associated with reduced LVEF and heart failure. Among 1139 patients without known heart disease in the Cardiovascular Health Study, the upper quartile of PVCs on 24-hour Holter monitoring (&gt;0.12 percent of total heart beats) was associated with reduced LVEF (odds ratio 3.1, 95% CI 1.4-6.8) or heart failure (odds ratio 1.5, 95% CI 1.1-2.0) over the next 10 years [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stroke </strong>– PVCs are associated with increased risk of stroke. In a prospective evaluation of 14,783 participants in the ARIC observational cohort, 6.1 percent had PVCs on a two-minute ECG, and 729 (4.9 percent) had incident stroke [<a href="#rid83">83</a>]. Incident strokes in individuals with any PVC was 6.6 percent compared with 4.1 percent in those without PVCs (HR 1.7, 95% CI 1.3-2.2). Similar findings were reported by the REGARDS study [<a href="#rid84">84</a>]. Whether this association relates to increased tendency toward formation of thrombi or embolization through cardiac remodeling or possibly atrial fibrillation or other reason, remains unknown.</p><p></p><p class="headingAnchor" id="H3049793512"><span class="h2">Heart failure or cardiomyopathy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure</strong> – In a Danish study of 850 patients with nonischemic systolic heart failure (LVEF &lt;35 percent), 350 patients with high-burden PVCs (≥30 PVCs in a 24-hour Holter monitor, 352 patients) had increased mortality (HR 1.38; 95% CI 1.00-1.90) and cardiovascular disease (HR 1.78, CI 1.19-2.66). However, they did not have a survival benefit from ICD implantation [<a href="#rid85">85</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients requiring resynchronization therapy </strong>–<strong> </strong>According to a MADIT-CRT substudy, among 698 patients with cardiac resynchronization therapy (CRT)-defibrillator (with ischemic and nonischemic cardiomyopathy), those with &gt;10 PVCs per hour, had significantly higher three-year risk of heart failure/death (25 versus 7 percent) and ventricular tachycardia/ventricular fibrillation (24 versus 8 percent) compared with those with a lower burden of ectopy [<a href="#rid86">86</a>]. Patients with &gt;10 PVCs-per-hour burden had approximately threefold increased risk of both heart failure/death (HR 2.8) and ventricular tachycardia/ventricular fibrillation (HR 2.8). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other cardiomyopathy </strong>– In patients with hypertrophic cardiomyopathy, PVCs are common, but unlike nonsustained ventricular tachycardia, PVCs have not been associated with an increased risk of sudden cardiac death. (See  <a class="medical medical_review" href="/z/d/html/4952.html" rel="external">"Hypertrophic cardiomyopathy: Risk stratification for sudden cardiac death"</a>.)</p><p></p><p class="bulletIndent1">In patients with arrhythmogenic right ventricular dysplasia, frequent PVCs and/or the presence of nonsustained ventricular tachycardia are markers of increased arrhythmic risk [<a href="#rid87">87</a>]. (See  <a class="medical medical_review" href="/z/d/html/4932.html" rel="external">"Arrhythmogenic right ventricular cardiomyopathy: Treatment and prognosis", section on 'Prognosis'</a>.)</p><p></p><p class="bulletIndent1">In patients with cardiac sarcoidosis, PVCs can help identify patients in whom an electrophysiologic study would be helpful in decision-making for implantable cardioverter-defibrillator placement/sudden cardiac death prevention. (See  <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis"</a>.)</p><p></p><p class="headingAnchor" id="H2864469089"><span class="h2">Exercise-induced premature ventricular complexes</span><span class="headingEndMark"> — </span>The prognostic significance of exercise-induced PVCs is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1548.html" rel="external">"Prognostic features of stress testing in patients with known or suspected coronary disease", section on 'Premature ventricular complexes'</a>.)</p><p class="headingAnchor" id="H1067617336"><span class="h1">PREGNANCY</span><span class="headingEndMark"> — </span>PVCs occurring during pregnancy constitute a special situation, where antiarrhythmic agents should be avoided if at all possible, especially during the first trimester, due to the risks posed for the embryo [<a href="#rid88">88</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Triggers</strong> – Some experts counsel patients with palpitations to discontinue potential precipitant factors such as smoking, coffee intake, alcohol intake, and other stimulants [<a href="#rid89">89</a>]. However, the role of caffeine restriction has not been established. Moderate caffeine exposure has not been demonstrated to increase PVCs in patients with or without structural heart disease [<a href="#rid90">90,91</a>], and caffeine restriction was not found to improve symptoms or reduce the frequency of PVCs in a small trial [<a href="#rid92">92</a>]. </p><p></p><p>However, frequent and/or symptomatic PVCs may need treatment, mainly with the use of beta blockers (eg, <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> or <a class="drug drug_general" data-topicid="9158" href="/z/d/drug information/9158.html" rel="external">bisoprolol</a>). Ablation, if at all needed, should be postponed until the postpartum period. It is reasonable to check electrolytes (eg, potassium, magnesium) in pregnant patients with symptomatic and frequent PVCs, as these are not part of the routine prenatal laboratory measurements, and abnormal levels can be treated.  </p><p>The presence of PVCs in pregnancy has not been shown to cause a worse prognosis. Among a cohort of 49 pregnant women with a structurally normal heart and "high" PVC burden (median PVC burden approximately 9 percent), overall maternal outcomes were favorable [<a href="#rid93">93</a>]. Although 11 percent of pregnancies were complicated by a cardiac event, all were successfully managed with medical therapy, mostly with beta blockers. With the exception of one patient requiring ventricular tachycardia ablation postpartum, no further therapy was required in the postpartum period, and PVC burden was found to decrease. The rate of adverse obstetric and fetal/neonatal outcomes in the PVC group was comparable to the normal pregnant population. </p><p class="headingAnchor" id="H2122652306"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116932.html" rel="external">"Society guideline links: Catheter ablation of arrhythmias"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/115586.html" rel="external">"Society guideline links: Ventricular arrhythmias"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">"Society guideline links: Arrhythmias in adults"</a>.)</p><p class="headingAnchor" id="H2429068943"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83178.html" rel="external">"Patient education: Ventricular premature beats (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H498403550"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction </strong>– Premature ventricular complexes/contractions (PVCs; also referred to as premature ventricular beats, premature ventricular depolarizations, or ventricular extrasystoles) are common and can occur in patients with and without apparent structural heart disease. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk stratification </strong>– Risk stratification is important to determine treatment and is based on symptoms, family history, high PVC burden (&gt;15 percent or 10,000 PVCs in 24 hours) and key PVC characteristics. (See <a class="local">'Risk assessment'</a> above.)</p><p></p><p class="bulletIndent1">All patients should have triggers identified and eliminated  (<a class="graphic graphic_table graphicRef138370" href="/z/d/graphic/138370.html" rel="external">table 1</a>). Our treatment approach is summarized in an algorithm  (<a class="graphic graphic_algorithm graphicRef126128" href="/z/d/graphic/126128.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with PVC-induced cardiomyopathy </strong>– Management of patients with reduced left ventricular ejection fraction (LVEF; &lt;50 percent) thought to be related to frequent PVCs is as follows (See <a class="local">'Premature ventricular complex cardiomyopathy'</a> above.):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with PVC-induced cardiomyopathy, we suggest initial therapy with a beta blocker (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). There is low threshold to proceeding with catheter ablation if the PVC burden remains high or the LVEF does not improve. (See <a class="local">'Beta blockers'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with signs and symptoms of heart failure due to suspected PVC-induced cardiomyopathy, we suggest initial treatment with catheter ablation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Heart failure treatment and beta blocker therapy are also appropriate. (See <a class="local">'Catheter ablation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with cardiac disease</strong> – For patients in whom underlying structural or electrical heart disease is identified, management focuses on providing appropriate therapy tailored to the specific underlying condition. Components of this therapy (eg, beta blockers) can contribute to a reduction in PVCs. Calcium channel blockers should be avoided in patients with cardiomyopathy and/or heart failure. (See <a class="local">'Preexisting cardiac disease'</a> above and  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Beta blocker'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic patients with low PVC burden and no structural heart disease </strong>– Asymptomatic patients with low PVC burden and no underlying heart disease generally do not require treatment. (See <a class="local">'Asymptomatic patients with low premature ventricular complex burden'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-risk patients with symptoms and/or high PVC burden</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial medical therapy</strong> – For most patients with symptomatic PVCs, we suggest first-line therapy with a beta blocker (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). A non-dihydropyridine calcium channel blocker is a reasonable alternative in patients without cardiomyopathy (See <a class="local">'Patient with symptoms and/or high premature ventricular complex burden'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subsequent therapy</strong> – For patients with persistent PVC-related symptoms on initial medical therapy or not tolerating medical therapy due to adverse effects, we suggest catheter ablation, rather than antiarrhythmic drug therapy, as the next treatment (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Catheter ablation likely has greater long-term efficacy and avoids antiarrhythmic drug toxicity. Class IC antiarrhythmic drug treatment is a reasonable alternative for patients without apparent structural heart disease who do not have access to catheter ablation or prefer to avoid an invasive procedure. Off-label use of <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> has also been suggested to effectively suppress PVCs without causing proarrhythmia. (See <a class="local">'Catheter ablation'</a> above and <a class="local">'Antiarrhythmic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>– The presence of simple, frequent, complex, or exercise-induced PVCs in patients with apparently normal hearts is associated with increased mortality. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1">Exercise-induced PVCs are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1548.html" rel="external">"Prognostic features of stress testing in patients with known or suspected coronary disease", section on 'Premature ventricular complexes'</a>.)</p><p></p><p class="headingAnchor" id="H2211446462"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Philip J Podrid, MD, FACC, Brian Olshansky, MD, and Bernard Gersh, MB, ChB, DPhil, FRCP, MACC, who contributed to an earlier version of this topic review. </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36:2793.</a></li><li><a class="nounderline abstract_t">Lip GY, Heinzel FR, Gaita F, et al. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2016; 18:12.</a></li><li><a class="nounderline abstract_t">Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2018; 15:e190.</a></li><li><a class="nounderline abstract_t">Dukes JW, Dewland TA, Vittinghoff E, et al. Ventricular Ectopy as a Predictor of Heart Failure and Death. J Am Coll Cardiol 2015; 66:101.</a></li><li><a class="nounderline abstract_t">Ip JE, Lerman BB. Idiopathic malignant premature ventricular contractions. Trends Cardiovasc Med 2018; 28:295.</a></li><li><a class="nounderline abstract_t">Dabbagh GS, Bogun F. Predictors and Therapy of Cardiomyopathy Caused by Frequent Ventricular Ectopy. Curr Cardiol Rep 2017; 19:80.</a></li><li><a class="nounderline abstract_t">Supple GE. Editorial commentary: Malignant PVCs: Revising the 'idiopathic' label. Trends Cardiovasc Med 2018; 28:303.</a></li><li><a class="nounderline abstract_t">Carballeira Pol L, Deyell MW, Frankel DS, et al. Ventricular premature depolarization QRS duration as a new marker of risk for the development of ventricular premature depolarization-induced cardiomyopathy. Heart Rhythm 2014; 11:299.</a></li><li><a class="nounderline abstract_t">Park KM, Im SI, Lee SH, et al. Left Ventricular Dysfunction in Outpatients with Frequent Ventricular Premature Complexes. Tex Heart Inst J 2022; 49.</a></li><li><a class="nounderline abstract_t">Yokokawa M, Kim HM, Good E, et al. Impact of QRS duration of frequent premature ventricular complexes on the development of cardiomyopathy. Heart Rhythm 2012; 9:1460.</a></li><li><a class="nounderline abstract_t">Yamada T. Twelve-lead electrocardiographic localization of idiopathic premature ventricular contraction origins. J Cardiovasc Electrophysiol 2019; 30:2603.</a></li><li><a class="nounderline abstract_t">Park KM, Kim YH, Marchlinski FE. Using the surface electrocardiogram to localize the origin of idiopathic ventricular tachycardia. Pacing Clin Electrophysiol 2012; 35:1516.</a></li><li><a class="nounderline abstract_t">Olgun H, Yokokawa M, Baman T, et al. The role of interpolation in PVC-induced cardiomyopathy. Heart Rhythm 2011; 8:1046.</a></li><li><a class="nounderline abstract_t">Viskin S, Lesh MD, Eldar M, et al. Mode of onset of malignant ventricular arrhythmias in idiopathic ventricular fibrillation. J Cardiovasc Electrophysiol 1997; 8:1115.</a></li><li><a class="nounderline abstract_t">Leenhardt A, Glaser E, Burguera M, et al. Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. Circulation 1994; 89:206.</a></li><li><a class="nounderline abstract_t">Sadek MM, Benhayon D, Sureddi R, et al. Idiopathic ventricular arrhythmias originating from the moderator band: Electrocardiographic characteristics and treatment by catheter ablation. Heart Rhythm 2015; 12:67.</a></li><li><a class="nounderline abstract_t">Lin CY, Chang SL, Lin YJ, et al. Long-term outcome of multiform premature ventricular complexes in structurally normal heart. Int J Cardiol 2015; 180:80.</a></li><li><a class="nounderline abstract_t">Bradfield JS, Homsi M, Shivkumar K, Miller JM. Coupling interval variability differentiates ventricular ectopic complexes arising in the aortic sinus of valsalva and great cardiac vein from other sources: mechanistic and arrhythmic risk implications. J Am Coll Cardiol 2014; 63:2151.</a></li><li><a class="nounderline abstract_t">Limpitikul WB, Dewland TA, Vittinghoff E, et al. Premature ventricular complexes and development of heart failure in a community-based population. Heart 2022; 108:105.</a></li><li><a class="nounderline abstract_t">Shimizu W. Arrhythmias originating from the right ventricular outflow tract: how to distinguish "malignant" from "benign"? Heart Rhythm 2009; 6:1507.</a></li><li><a class="nounderline abstract_t">Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initiated by premature extrasystoles originating from the right ventricular outflow tract. J Am Coll Cardiol 2005; 46:1288.</a></li><li><a class="nounderline abstract_t">Abdalla IS, Prineas RJ, Neaton JD, et al. Relation between ventricular premature complexes and sudden cardiac death in apparently healthy men. Am J Cardiol 1987; 60:1036.</a></li><li><a class="nounderline abstract_t">Sajadieh A, Nielsen OW, Rasmussen V, et al. Ventricular arrhythmias and risk of death and acute myocardial infarction in apparently healthy subjects of age &gt;or=55 years. Am J Cardiol 2006; 97:1351.</a></li><li><a class="nounderline abstract_t">Bikkina M, Larson MG, Levy D. Prognostic implications of asymptomatic ventricular arrhythmias: the Framingham Heart Study. Ann Intern Med 1992; 117:990.</a></li><li><a class="nounderline abstract_t">Gopinathannair R, Etheridge SP, Marchlinski FE, et al. Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management. J Am Coll Cardiol 2015; 66:1714.</a></li><li><a class="nounderline abstract_t">Lee AK, Deyell MW. Premature ventricular contraction-induced cardiomyopathy. Curr Opin Cardiol 2016; 31:1.</a></li><li><a class="nounderline abstract_t">Latchamsetty R, Yokokawa M, Morady F, et al. Multicenter Outcomes for Catheter Ablation of Idiopathic Premature Ventricular Complexes. JACC Clin Electrophysiol 2015; 1:116.</a></li><li><a class="nounderline abstract_t">Giles K, Green MS. Workup and management of patients with frequent premature ventricular contractions. Can J Cardiol 2013; 29:1512.</a></li><li><a class="nounderline abstract_t">Manolis AA, Manolis TA, Apostolopoulos EJ, et al. The role of the autonomic nervous system in cardiac arrhythmias: The neuro-cardiac axis, more foe than friend? Trends Cardiovasc Med 2021; 31:290.</a></li><li><a class="nounderline abstract_t">Yokokawa M, Siontis KC, Kim HM, et al. Value of cardiac magnetic resonance imaging and programmed ventricular stimulation in patients with frequent premature ventricular complexes undergoing radiofrequency ablation. Heart Rhythm 2017; 14:1695.</a></li><li><a class="nounderline abstract_t">Yamada T. Idiopathic ventricular arrhythmias: Relevance to the anatomy, diagnosis and treatment. J Cardiol 2016; 68:463.</a></li><li><a class="nounderline abstract_t">Oebel S, Dinov B, Arya A, et al. ECG morphology of premature ventricular contractions predicts the presence of myocardial fibrotic substrate on cardiac magnetic resonance imaging in patients undergoing ablation. J Cardiovasc Electrophysiol 2017; 28:1316.</a></li><li><a class="nounderline abstract_t">Brunetti G, Cipriani A, Perazzolo Marra M, et al. Role of Cardiac Magnetic Resonance Imaging in the Evaluation of Athletes with Premature Ventricular Beats. J Clin Med 2022; 11.</a></li><li><a class="nounderline abstract_t">Muser D, Santangeli P, Castro SA, et al. Risk Stratification of Patients With Apparently Idiopathic Premature Ventricular Contractions: A Multicenter International CMR Registry. JACC Clin Electrophysiol 2020; 6:722.</a></li><li><a class="nounderline abstract_t">Hosseini F, Thibert MJ, Gulsin GS, et al. Cardiac Magnetic Resonance in the Evaluation of Patients With Frequent Premature Ventricular Complexes. JACC Clin Electrophysiol 2022; 8:1122.</a></li><li><a class="nounderline abstract_t">Pellegrino PL, Casavecchia G, Gravina M, et al. Concealed structural heart disease discovered at cardiac magnetic resonance in patients with ventricular extrasystoles from ventricular outflow tract and apparently normal hearts. J Interv Card Electrophysiol 2021; 61:45.</a></li><li><a class="nounderline abstract_t">Lip GYH, Coca A, Kahan T, et al. Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace 2017; 19:891.</a></li><li><a class="nounderline abstract_t">Muser D, Tritto M, Mariani MV, et al. Diagnosis and Treatment of Idiopathic Premature Ventricular Contractions: A Stepwise Approach Based on the Site of Origin. Diagnostics (Basel) 2021; 11.</a></li><li><a class="nounderline abstract_t">Ghannam M, Siontis KC, Kim MH, et al. Risk stratification in patients with frequent premature ventricular complexes in the absence of known heart disease. Heart Rhythm 2020; 17:423.</a></li><li><a class="nounderline abstract_t">Tang JKK, Andrade JG, Hawkins NM, et al. Effectiveness of medical therapy for treatment of idiopathic frequent premature ventricular complexes. J Cardiovasc Electrophysiol 2021; 32:2246.</a></li><li><a class="nounderline abstract_t">Zhong L, Lee YH, Huang XM, et al. Relative efficacy of catheter ablation vs antiarrhythmic drugs in treating premature ventricular contractions: a single-center retrospective study. Heart Rhythm 2014; 11:187.</a></li><li><a class="nounderline abstract_t">Chandraratna PA. Comparison of acebutolol with propranolol, quinidine, and placebo: results of three multicenter arrhythmia trials. Am Heart J 1985; 109:1198.</a></li><li><a class="nounderline abstract_t">Hasdemir C, Ulucan C, Yavuzgil O, et al. Tachycardia-induced cardiomyopathy in patients with idiopathic ventricular arrhythmias: the incidence, clinical and electrophysiologic characteristics, and the predictors. J Cardiovasc Electrophysiol 2011; 22:663.</a></li><li><a class="nounderline abstract_t">Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm 2010; 7:865.</a></li><li><a class="nounderline abstract_t">Takemoto M, Yoshimura H, Ohba Y, et al. Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease. J Am Coll Cardiol 2005; 45:1259.</a></li><li><a class="nounderline abstract_t">Wijnmaalen AP, Delgado V, Schalij MJ, et al. Beneficial effects of catheter ablation on left ventricular and right ventricular function in patients with frequent premature ventricular contractions and preserved ejection fraction. Heart 2010; 96:1275.</a></li><li><a class="nounderline abstract_t">Yarlagadda RK, Iwai S, Stein KM, et al. Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract. Circulation 2005; 112:1092.</a></li><li><a class="nounderline abstract_t">Yokokawa M, Good E, Crawford T, et al. Recovery from left ventricular dysfunction after ablation of frequent premature ventricular complexes. Heart Rhythm 2013; 10:172.</a></li><li><a class="nounderline abstract_t">Marcus GM. Evaluation and Management of Premature Ventricular Complexes. Circulation 2020; 141:1404.</a></li><li><a class="nounderline abstract_t">Lamba J, Redfearn DP, Michael KA, et al. Radiofrequency catheter ablation for the treatment of idiopathic premature ventricular contractions originating from the right ventricular outflow tract: a systematic review and meta-analysis. Pacing Clin Electrophysiol 2014; 37:73.</a></li><li><a class="nounderline abstract_t">Deyell MW, Park KM, Han Y, et al. Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations. Heart Rhythm 2012; 9:1465.</a></li><li><a class="nounderline abstract_t">Im SI, Voskoboinik A, Lee A, et al. Predictors of long-term success after catheter ablation of premature ventricular complexes. J Cardiovasc Electrophysiol 2021; 32:2254.</a></li><li><a class="nounderline abstract_t">Oomen AWGJ, Dekker LRC, Meijer A. Catheter ablation of symptomatic idiopathic ventricular arrhythmias : A five-year single-centre experience. Neth Heart J 2018; 26:210.</a></li><li><a class="nounderline abstract_t">Wang JS, Shen YG, Yin RP, et al. The safety of catheter ablation for premature ventricular contractions in patients without structural heart disease. BMC Cardiovasc Disord 2018; 18:177.</a></li><li><a class="nounderline abstract_t">Cojocaru C, Penela D, Berruezo A, Vatasescu R. Mechanisms, time course and predictability of premature ventricular contractions cardiomyopathy-an update on its development and resolution. Heart Fail Rev 2022; 27:1639.</a></li><li><a class="nounderline abstract_t">Penela D, Jáuregui B, Fernández-Armenta J, et al. Influence of baseline QRS on the left ventricular ejection fraction recovery after frequent premature ventricular complex ablation. Europace 2020; 22:274.</a></li><li><a class="nounderline abstract_t">Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997; 349:675.</a></li><li><a class="nounderline abstract_t">Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 349:667.</a></li><li><a class="nounderline abstract_t">Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333:77.</a></li><li><a class="nounderline abstract_t">Murray GL. Ranolazine is an Effective and Safe Treatment of Adults with Symptomatic Premature Ventricular Contractions due to Triggered Ectopy. Int J Angiol 2016; 25:247.</a></li><li><a class="nounderline abstract_t">Yeung E, Krantz MJ, Schuller JL, et al. Ranolazine for the suppression of ventricular arrhythmia: a case series. Ann Noninvasive Electrocardiol 2014; 19:345.</a></li><li><a class="nounderline abstract_t">Nanda S, Levin V, Martinez MW, Freudenberger R. Ranolazine--treatment of ventricular tachycardia and symptomatic ventricular premature beats in ischemic cardiomyopathy. Pacing Clin Electrophysiol 2010; 33:e119.</a></li><li><a class="nounderline abstract_t">Murdock DK, Kaliebe JW. Suppression of frequent ventricular ectopy in a patient with hypertrophic heart disease with ranolazine: a case report. Indian Pacing Electrophysiol J 2011; 11:84.</a></li><li><a class="nounderline abstract_t">Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007; 116:1647.</a></li><li><a class="nounderline abstract_t">Polytarchou K, Manolis AS. Ranolazine and its Antiarrhythmic Actions. Cardiovasc Hematol Agents Med Chem 2015; 13:31.</a></li><li><a class="nounderline abstract_t">Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781.</a></li><li><a class="nounderline abstract_t">Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996; 348:7.</a></li><li><a class="nounderline abstract_t">Hyman MC, Mustin D, Supple G, et al. Class IC antiarrhythmic drugs for suspected premature ventricular contraction-induced cardiomyopathy. Heart Rhythm 2018; 15:159.</a></li><li><a class="nounderline abstract_t">Penela D, Acosta J, Aguinaga L, et al. Ablation of frequent PVC in patients meeting criteria for primary prevention ICD implant: Safety of withholding the implant. Heart Rhythm 2015; 12:2434.</a></li><li><a class="nounderline abstract_t">Podrid PJ, Fogel RI, Fuchs TT. Ventricular arrhythmia in congestive heart failure. Am J Cardiol 1992; 69:82G.</a></li><li><a class="nounderline abstract_t">Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986; 73:503.</a></li><li><a class="nounderline abstract_t">Lichstein E, Morganroth J, Harrist R, Hubble E. Effect of propranolol on ventricular arrhythmia. The beta-blocker heart attack trial experience. Circulation 1983; 67:I5.</a></li><li><a class="nounderline abstract_t">Manolis AS. The clinical challenge of preventing sudden cardiac death immediately after acute ST-elevation myocardial infarction. Expert Rev Cardiovasc Ther 2014; 12:1427.</a></li><li><a class="nounderline abstract_t">Hayes DL, Boehmer JP, Day JD, et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm 2011; 8:1469.</a></li><li><a class="nounderline abstract_t">Lakkireddy D, Di Biase L, Ryschon K, et al. Radiofrequency ablation of premature ventricular ectopy improves the efficacy of cardiac resynchronization therapy in nonresponders. J Am Coll Cardiol 2012; 60:1531.</a></li><li><a class="nounderline abstract_t">Yokokawa M, Kim HM, Good E, et al. Relation of symptoms and symptom duration to premature ventricular complex-induced cardiomyopathy. Heart Rhythm 2012; 9:92.</a></li><li><a class="nounderline abstract_t">Lee AKY, Andrade J, Hawkins NM, et al. Outcomes of untreated frequent premature ventricular complexes with normal left ventricular function. Heart 2019; 105:1408.</a></li><li><a class="nounderline abstract_t">Latchamsetty R, Bogun F. Premature Ventricular Complex-Induced Cardiomyopathy. JACC Clin Electrophysiol 2019; 5:537.</a></li><li><a class="nounderline abstract_t">Podrid PJ, Lampert S, Graboys TB, et al. Aggravation of arrhythmia by antiarrhythmic drugs--incidence and predictors. Am J Cardiol 1987; 59:38E.</a></li><li><a class="nounderline abstract_t">Madias C, Estes NAM 3rd. Class IC antiarrhythmic agents in structural heart disease: Is nothing CAST in stone? Heart Rhythm 2018; 15:164.</a></li><li><a class="nounderline abstract_t">Lee V, Hemingway H, Harb R, et al. The prognostic significance of premature ventricular complexes in adults without clinically apparent heart disease: a meta-analysis and systematic review. Heart 2012; 98:1290.</a></li><li><a class="nounderline abstract_t">Lin CY, Chang SL, Lin YJ, et al. An observational study on the effect of premature ventricular complex burden on long-term outcome. Medicine (Baltimore) 2017; 96:e5476.</a></li><li><a class="nounderline abstract_t">Agarwal SK, Heiss G, Rautaharju PM, et al. Premature ventricular complexes and the risk of incident stroke: the Atherosclerosis Risk In Communities (ARIC) Study. Stroke 2010; 41:588.</a></li><li><a class="nounderline abstract_t">Agarwal SK, Chao J, Peace F, et al. Premature ventricular complexes on screening electrocardiogram and risk of ischemic stroke. Stroke 2015; 46:1365.</a></li><li><a class="nounderline abstract_t">Boas R, Thune JJ, Pehrson S, et al. Prevalence and prognostic association of ventricular arrhythmia in non-ischaemic heart failure patients: results from the DANISH trial. Europace 2021; 23:587.</a></li><li><a class="nounderline abstract_t">Ruwald AC, Aktas MK, Ruwald MH, et al. Postimplantation ventricular ectopic burden and clinical outcomes in cardiac resynchronization therapy-defibrillator patients: a MADIT-CRT substudy. Ann Noninvasive Electrocardiol 2018; 23:e12491.</a></li><li><a class="nounderline abstract_t">Bhonsale A, James CA, Tichnell C, et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol 2011; 58:1485.</a></li><li><a class="nounderline abstract_t">Manolis TA, Manolis AA, Apostolopoulos EJ, et al. Cardiac arrhythmias in pregnant women: need for mother and offspring protection. Curr Med Res Opin 2020; 36:1225.</a></li><li><a class="nounderline abstract_t">Cox JL, Gardner MJ. Treatment of cardiac arrhythmias during pregnancy. Prog Cardiovasc Dis 1993; 36:137.</a></li><li><a class="nounderline abstract_t">Newcombe PF, Renton KW, Rautaharju PM, et al. High-dose caffeine and cardiac rate and rhythm in normal subjects. Chest 1988; 94:90.</a></li><li><a class="nounderline abstract_t">Myers MG. Caffeine and cardiac arrhythmias. Ann Intern Med 1991; 114:147.</a></li><li><a class="nounderline abstract_t">Newby DE, Neilson JM, Jarvie DR, Boon NA. Caffeine restriction has no role in the management of patients with symptomatic idiopathic ventricular premature beats. Heart 1996; 76:355.</a></li><li><a class="nounderline abstract_t">Tong C, Kiess M, Deyell MW, et al. Impact of frequent premature ventricular contractions on pregnancy outcomes. Heart 2018; 104:1370.</a></li></ol></div><div id="topicVersionRevision">Topic 122361 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320108" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26297713" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097320" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26160626" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Ventricular Ectopy as a Predictor of Heart Failure and Death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29254831" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Idiopathic malignant premature ventricular contractions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28752278" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Predictors and Therapy of Cardiomyopathy Caused by Frequent Ventricular Ectopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29307779" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Editorial commentary: Malignant PVCs: Revising the 'idiopathic' label.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24184787" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Ventricular premature depolarization QRS duration as a new marker of risk for the development of ventricular premature depolarization-induced cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35226106" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Left Ventricular Dysfunction in Outpatients with Frequent Ventricular Premature Complexes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22542704" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Impact of QRS duration of frequent premature ventricular complexes on the development of cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31502322" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Twelve-lead electrocardiographic localization of idiopathic premature ventricular contraction origins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22897344" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Using the surface electrocardiogram to localize the origin of idiopathic ventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21376837" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The role of interpolation in PVC-induced cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9363814" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mode of onset of malignant ventricular arrhythmias in idiopathic ventricular fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8281648" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25240695" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Idiopathic ventricular arrhythmias originating from the moderator band: Electrocardiographic characteristics and treatment by catheter ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25438221" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Long-term outcome of multiform premature ventricular complexes in structurally normal heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24657687" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Coupling interval variability differentiates ventricular ectopic complexes arising in the aortic sinus of valsalva and great cardiac vein from other sources: mechanistic and arrhythmic risk implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34493549" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Premature ventricular complexes and development of heart failure in a community-based population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19695964" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Arrhythmias originating from the right ventricular outflow tract: how to distinguish "malignant" from "benign"?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16198845" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initiated by premature extrasystoles originating from the right ventricular outflow tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3673904" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Relation between ventricular premature complexes and sudden cardiac death in apparently healthy men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16635610" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Ventricular arrhythmias and risk of death and acute myocardial infarction in apparently healthy subjects of age&gt;or=55 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1280018" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prognostic implications of asymptomatic ventricular arrhythmias: the Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26449143" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26599061" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Premature ventricular contraction-induced cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29759353" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Multicenter Outcomes for Catheter Ablation of Idiopathic Premature Ventricular Complexes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24182757" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Workup and management of patients with frequent premature ventricular contractions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32434043" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The role of the autonomic nervous system in cardiac arrhythmias: The neuro-cardiac axis, more foe than friend?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28688990" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Value of cardiac magnetic resonance imaging and programmed ventricular stimulation in patients with frequent premature ventricular complexes undergoing radiofrequency ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27401396" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Idiopathic ventricular arrhythmias: Relevance to the anatomy, diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28791747" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : ECG morphology of premature ventricular contractions predicts the presence of myocardial fibrotic substrate on cardiac magnetic resonance imaging in patients undergoing ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35054118" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Role of Cardiac Magnetic Resonance Imaging in the Evaluation of Athletes with Premature Ventricular Beats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32553224" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Risk Stratification of Patients With Apparently Idiopathic Premature Ventricular Contractions: A Multicenter International CMR Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36137717" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cardiac Magnetic Resonance in the Evaluation of Patients With Frequent Premature Ventricular Complexes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32462549" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Concealed structural heart disease discovered at cardiac magnetic resonance in patients with ventricular extrasystoles from ventricular outflow tract and apparently normal hearts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28881872" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34679539" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Diagnosis and Treatment of Idiopathic Premature Ventricular Contractions: A Stepwise Approach Based on the Site of Origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31580899" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Risk stratification in patients with frequent premature ventricular complexes in the absence of known heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34216056" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effectiveness of medical therapy for treatment of idiopathic frequent premature ventricular complexes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24157533" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Relative efficacy of catheter ablation vs antiarrhythmic drugs in treating premature ventricular contractions: a single-center retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3993535" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Comparison of acebutolol with propranolol, quinidine, and placebo: results of three multicenter arrhythmia trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21235667" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Tachycardia-induced cardiomyopathy in patients with idiopathic ventricular arrhythmias: the incidence, clinical and electrophysiologic characteristics, and the predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20348027" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Relationship between burden of premature ventricular complexes and left ventricular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15837259" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20659945" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Beneficial effects of catheter ablation on left ventricular and right ventricular function in patients with frequent premature ventricular contractions and preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16103234" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23099051" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Recovery from left ventricular dysfunction after ablation of frequent premature ventricular complexes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32339046" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Evaluation and Management of Premature Ventricular Complexes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23980900" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Radiofrequency catheter ablation for the treatment of idiopathic premature ventricular contractions originating from the right ventricular outflow tract: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22640894" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34041816" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Predictors of long-term success after catheter ablation of premature ventricular complexes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29383491" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Catheter ablation of symptomatic idiopathic ventricular arrhythmias : A five-year single-centre experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30170545" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The safety of catheter ablation for premature ventricular contractions in patients without structural heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34510326" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Mechanisms, time course and predictability of premature ventricular contractions cardiomyopathy-an update on its development and resolution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31942618" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Influence of baseline QRS on the left ventricular ejection fraction recovery after frequent premature ventricular complex ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9078198" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9078197" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7539890" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27867290" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Ranolazine is an Effective and Safe Treatment of Adults with Symptomatic Premature Ventricular Contractions due to Triggered Ectopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24533675" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Ranolazine for the suppression of ventricular arrhythmia: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20345626" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Ranolazine--treatment of ventricular tachycardia and symptomatic ventricular premature beats in ischemic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21556158" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Suppression of frequent ventricular ectopy in a patient with hypertrophic heart disease with ranolazine: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17804441" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26245658" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Ranolazine and its Antiarrhythmic Actions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1900101" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8691967" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29405947" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Class IC antiarrhythmic drugs for suspected premature ventricular contraction-induced cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26385530" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Ablation of frequent PVC in patients meeting criteria for primary prevention ICD implant: Safety of withholding the implant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1626494" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Ventricular arrhythmia in congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3948357" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effect of propranolol after acute myocardial infarction in patients with congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6342839" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Effect of propranolol on ventricular arrhythmia. The beta-blocker heart attack trial experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25382137" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The clinical challenge of preventing sudden cardiac death immediately after acute ST-elevation myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21699828" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22999718" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Radiofrequency ablation of premature ventricular ectopy improves the efficacy of cardiac resynchronization therapy in nonresponders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21855522" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Relation of symptoms and symptom duration to premature ventricular complex-induced cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31142596" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Outcomes of untreated frequent premature ventricular complexes with normal left ventricular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31122375" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Premature Ventricular Complex-Induced Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2437788" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Aggravation of arrhythmia by antiarrhythmic drugs--incidence and predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29405948" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Class IC antiarrhythmic agents in structural heart disease: Is nothing CAST in stone?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22781425" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The prognostic significance of premature ventricular complexes in adults without clinically apparent heart disease: a meta-analysis and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28072689" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : An observational study on the effect of premature ventricular complex burden on long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20167922" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Premature ventricular complexes and the risk of incident stroke: the Atherosclerosis Risk In Communities (ARIC) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25873602" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Premature ventricular complexes on screening electrocardiogram and risk of ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33257933" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Prevalence and prognostic association of ventricular arrhythmia in non-ischaemic heart failure patients: results from the DANISH trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28940909" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Postimplantation ventricular ectopic burden and clinical outcomes in cardiac resynchronization therapy-defibrillator patients: a MADIT-CRT substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21939834" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32347120" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cardiac arrhythmias in pregnant women: need for mother and offspring protection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8103603" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Treatment of cardiac arrhythmias during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2454782" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : High-dose caffeine and cardiac rate and rhythm in normal subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984393" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Caffeine and cardiac arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8983684" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Caffeine restriction has no role in the management of patients with symptomatic idiopathic ventricular premature beats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29463610" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Impact of frequent premature ventricular contractions on pregnancy outcomes.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
